Fulcrum Therapeutics, Inc.
Financials
Valuation Metrics
Fulcrum Therapeutics, Inc.'s Market Cap is $279M. At end of 2025 it was $717M. Ranked #2914 of 3,116 in US market (top 94%), #1314 of 1,472 on NASDAQ (top 89%), #235 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 89%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $279M | US#2,914/3,116 Sec#235/265 |
| Revenue | $0.00 | US#2,859/3,116 Sec#193/265 |
| Net Income | $-85M | US—/3,116 Sec—/265 |
| Total Assets | $324M | US#2,888/3,116 Sec#201/265 |
| Net Assets | $311M | US#2,493/3,116 Sec#156/265 |
| Employees | 9 | US#2,771/3,116 Sec#222/265 |
| Value | ||
| P/B | 0.90x | US#339/3,116 Sec#18/265 |
| FCF Yield | -23.69% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -27.36% | US#2,539/3,116 Sec#110/265 |
| ROA | -26.24% | US#2,854/3,116 Sec#149/265 |
| Financial Health | ||
| Debt Ratio | 4.27% | US#34/3,116 Sec#10/265 |
| Total Debt | $5M | US#2,887/3,116 Sec#213/265 |
| FCF | $-66M | US#2,562/3,116 Sec#121/265 |
| Cash | $48M | US#2,579/3,116 Sec#226/265 |
| Current Ratio | 31.35x | US#78/3,116 Sec#10/265 |
| Performance | ||
| 1Y Return | -58.17% | US#2,976/3,116 Sec#246/265 |
| 1M Return | -0.81% | US#1,653/3,116 Sec#108/265 |
| From 52W High | -76.75% | US#3,026/3,116 Sec#246/265 |
| 1Y MDD | -78.49% | US#3,027/3,116 Sec#243/265 |
| Trading | ||
| Volume | 1,108,206 shares | US#1,095/3,116 Sec#106/265 |
| Trading Value | $4M | US#2,571/3,116 Sec#208/265 |
| Per Share | ||
| EPS | $-1.11 | US—/3,116 Sec—/265 |
| BPS | $4.07 | US#2,344/3,116 Sec#137/265 |
Company Info
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.